Brian Lundstrom, PhD
Epilepsy · Rochester, MNNPI 1255630182
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,410 of the $8,718 with a category attached, or 73.5%. 3 manufacturers reported payments, led by Medtronic at 53.8% of the total. Reporting peaked in 2023 at $5,429 and has fallen 77.9% since, to $1,200 in 2024.
Across 16 payments — averaging $544.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$5K
- Neuropace, Inc.$3K
- DIXI Medical USA Corp$833
Across 41 payments — averaging $3123.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$113K
- Neuropace, Inc.$15K
What the payments were for
- Consulting fees$6,41074%
- Travel & lodging$7759%
- Food & beverage$1,53318%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 10 | $4,688 |
| Neuropace, Inc. | 5 | $3,197 |
| DIXI Medical USA Corp | 1 | $833 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PERCEPT PC BRAINSENSE$3,200
- RNS Neurostimulator Kit$3,176
- ACTIVA$262
- ACTIVA PC$101
How this compares
Too few epilepsy providers in Minnesotato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 21 | $31,282 |
| Lamotrigine ErLamotrigine | 12 | $3,779 |
| Lacosamide | 22 | $2,544 |
| Levetiracetam | 21 | $1,583 |
| Clobazam | 15 | $1,153 |
| Clonazepam | 16 | $119 |
Paid to pharmacies, not to this prescriber.
Other epilepsy in Rochester
- Elaine WirrellRochester$160K
- Katherine NickelsRochester$23K
- Gregory WorrellRochester$11K
- Kelsey SmithRochester$3K
- Christopher SanfilippoRochester$1K
- David BurkholderRochester$714
- Nicholas GreggRochester$312
- Anthony FineRochester$231
- Gregory CascinoRochester$203
- Hicham DabajaRochester$195
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.